Table 1.
Baseline Patient Characteristics of the Entire ROMICAT Trial Cohort, Those With Complete Follow-Up, and Those Lost From Follow-Up
| Total Cohort (N = 368) | Follow-up (n = 333) | Lost to Follow-up (n = 35) | p Value | |
|---|---|---|---|---|
| Demographics | ||||
| Age, yrs | 52.8 ±11.8 | 53.3 ±11.8 | 47.6 ± 10.7 | 0.006 |
| Male | 226 (61.4) | 199 (59.8) | 27 (77.1) | 0.05 |
| Body mass index, kg/m2 | 29.0 ±6.0 | 29.4 ±5.9 | 29.0 ± 6.0 | 0.64 |
|
| ||||
| Risk factors | ||||
| Diabetes mellitus | 40 (10.9) | 32 (9.6) | 8 (22.9) | 0.04 |
| Hypertension | 145 (39.4) | 135 (40.5) | 10 (28.6) | 0.20 |
| Hyperlipidemia | 135 (36.7) | 129 (38.7) | 6 (17.1) | 0.02 |
| Smoking | 180 (48.9) | 167 (50.2) | 13 (37.1) | 0.16 |
| Family history of CAD | 89 (24.2) | 78 (23.4) | 11 (31.4) | 0.30 |
|
| ||||
| TIMI risks for UA/NSTEMI | 0.74 | |||
| 0–2 points | 347 (94.3) | 313 (94.0) | 34 (97.1) | |
| 3–4 points | 20 (5.4) | 19 (5.7) | 1 (2.9) | |
| 5–7 points | 1 (0.3) | 1 (0.3) | 0 (0) | |
|
| ||||
| Medications at baseline | ||||
| Aspirin | 117 (31.8) | 112 (33.6) | 5 (14.3) | 0.02 |
| Beta-blockers | 84 (22.8) | 82 (24.6) | 2 (5.7) | 0.01 |
| Statins | 103 (28.0) | 98 (29.4) | 5 (14.3) | 0.07 |
| ACE-I | 56 (15.2) | 53 (15.9) | 3 (8.6) | 0.33 |
| Any of the above medications | 204 (55.4) | 192 (57.7) | 12 (34.3) | 0.01 |
|
| ||||
| Features of cardiac CT | ||||
| CAD categories | 0.06 | |||
| No CAD | 183 (49.7) | 159 (47.8) | 24 (68.6) | |
| Nonobstructive CAD | 117 (31.8) | 111 (33.3) | 6 (17.4) | |
| Obstructive CAD | 68 (18.9) | 63 (18.9) | 5 (14.3) | |
| RWMA | 46 (12.5) | 44 (13.2) | 2 (5.7) | 0.28 |
Values are mean ± SD or n (%).
ACE-I = angiotensin-converting enzyme inhibitor; CAD = coronary artery disease; CT = computed tomography; RWMA = regional wall motion abnormalities; TIMI = Thrombolysis In Myocardial Infarction; UA/NSTEMI = unstable angina/non–ST-segment elevation myocardial infarction.